NCI’s Research Buying Power is $1.1 Billion Less than 20 Years Ago
Add to My Pictures
|Title:||NCI’s Research Buying Power is $1.1 Billion Less than 20 Years Ago|
The increasing cost of research and clinical trials has significantly eroded NCI’s ability to fund research by reducing the buying power of NCI’s budget. In fact, based on the Biomedical Research and Development Price Index (BRDPI), NCI has 13% less buying power than it did 20 years ago. That 13% reduction translates to a budget that can fund $1.1 billion less research in 2023 than it did in 2003.
Despite a budget increase in FY23 from a supportive Congress, NCI still faced difficult choices: having to balance the increased investment in R01 grants with other demands for investment, including clinical trials, training programs, and research infrastructure.
This image is part of the NCI Fiscal Year 2025 Professional Judgment Budget Proposal: Leading Progress against Cancer collection.
See also www.cancer.gov/research/leading-progress.
|Type:||Color, Diagram (JPEG format)|
|Source:||National Cancer Institute (NCI)|
|Date Created:||September 19, 2023|
|Date Added:||September 23, 2023|
|Reuse Restrictions:||None - This image is in the public domain and can be freely reused. Please credit the source and, where possible, the creator listed above.|